Literature DB >> 15621268

Electron transfer kinetics and mechanistic study of the thionicotinamide coordinated to the pentacyanoferrate(III)/(II) complexes: a model system for the in vitro activation of thioamides anti-tuberculosis drugs.

Eduardo H S Sousa1, Daniel L Pontes, Izaura C N Diógenes, Luiz G F Lopes, Jaim S Oliveira, Luiz A Basso, Diógenes S Santos, Icaro S Moreira.   

Abstract

The mechanism of activation thioamide-pyridine anti-tuberculosis prodrugs is poorly described in the literature. It has recently been shown that ethionamide, an important component of second-line therapy for the treatment of multi-drug-resistant tuberculosis, is activated through an enzymatic electron transfer (ET) reaction. In an attempt to shed light on the activation of thioamide drugs, we have mimicked a redox process involving the thionicotinamide (thio) ligand, investigating its reactivity through coordination to the redox reversible [Fe(III/II)(CN)(5)(H(2)O)](2-/3-) metal center. The reaction of the Fe(III) complex with thionicotinamide leads to the ligand conversion to the 3-cyanopyridine species coordinated to a Fe(II) metal center. The rate constant, k(et)=10 s(-1), was determined for this intra-molecular ET reaction. A kinetic study for the cross-reaction of thionicotinamide and [Fe(CN)(6)](3-) was also carried out. The oxidation of thionicotinamide by [Fe(CN)(6)](3-) leads to formation of mainly 3-cyanopyridine and [Fe(CN)(6)](4-) with a k(et)=(5.38+/-0.03) M(-1)s(-1) at 25 degrees C, pH 12.0. The rate of this reaction is strongly dependent on pH due to an acid-base equilibrium related to the deprotonation of the R-SH functional group of the imidothiol form of thionicotinamide. The kinetic results reinforced the assignment of an intra-molecular mechanism for the ET reaction of [Fe(III)(CN)(5)(H(2)O)](2-) and the thioamide ligand. These results can be valuable for the design of new thiocarbonyl-containing drugs against resistant strains of Mycobacterium tuberculosis by a self-activating mechanism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15621268     DOI: 10.1016/j.jinorgbio.2004.10.004

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  4 in total

1.  Isoniazid metal complex reactivity and insights for a novel anti-tuberculosis drug design.

Authors:  Eduardo Henrique Silva Sousa; Luiz Augusto Basso; Diógenes S Santos; Izaura Cirino Nogueira Diógenes; Elisane Longhinotti; Luiz Gonzaga de França Lopes; Icaro de Sousa Moreira
Journal:  J Biol Inorg Chem       Date:  2011-09-28       Impact factor: 3.358

2.  High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv.

Authors:  Subramaniam Ananthan; Ellen R Faaleolea; Robert C Goldman; Judith V Hobrath; Cecil D Kwong; Barbara E Laughon; Joseph A Maddry; Alka Mehta; Lynn Rasmussen; Robert C Reynolds; John A Secrist; Nice Shindo; Dustin N Showe; Melinda I Sosa; William J Suling; E Lucile White
Journal:  Tuberculosis (Edinb)       Date:  2009-09-15       Impact factor: 3.131

3.  Pentacyanoferrate(II) complex of pyridine-4- and pyrazine-2-hydroxamic acid as source of HNO: investigation of anti-tubercular and vasodilation activities.

Authors:  Edinilton Muniz Carvalho; Tercio de Freitas Paulo; Alix Sournia Saquet; Bruno Lopes Abbadi; Fernanda Souza Macchi; Cristiano Valim Bizarro; Rafael de Morais Campos; Talles Luann Abrantes Ferreira; Nilberto Robson Falcão do Nascimento; Luiz Gonzaga França Lopes; Remi Chauvin; Eduardo Henrique Silva Sousa; Vania Bernardes-Génisson
Journal:  J Biol Inorg Chem       Date:  2020-07-29       Impact factor: 3.358

Review 4.  Is IQG-607 a Potential Metallodrug or Metallopro-Drug With a Defined Molecular Target in Mycobacterium tuberculosis?

Authors:  Bruno L Abbadi; Valnês da Silva Rodrigues-Junior; Adilio da Silva Dadda; Kenia Pissinate; Anne D Villela; Maria M Campos; Luiz G de França Lopes; Cristiano V Bizarro; Pablo Machado; Eduardo H S Sousa; Luiz A Basso
Journal:  Front Microbiol       Date:  2018-05-01       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.